On 4 May 2026, the European Commission adopted Commission Implementing Regulation (EU) 2026/977, rewriting how notified bodies run conformity assessment under both the MDR and the IVDR. The headline is predictability: maximum timelines, a cap on how often the clock can stop, and cost transparency. The part worth reading past the headline is what the regulation does not do — and when it actually starts to bind.

What the regulation actually changes

This is a revision to Annex VII of the MDR and IVDR — the provisions governing how notified bodies themselves operate, not the conformity assessment routes manufacturers choose between under Annexes IX, X, and XI, and not the sampling plan that already governs which technical documentation files a notified body reads in full. Route choice and sampling are unchanged. What changes is the discipline the notified body itself is held to once a manufacturer is inside one of those routes: how long each phase of review may take, how many times the clock may be stopped, what the notified body must disclose about cost, and what it must report publicly about its own performance.

4 May 2026
Adoption date of Commission Implementing Regulation (EU) 2026/977.
25 Feb 2027
General application date — the point new agreements fall under the new timeline rules.
10%
The cost overrun threshold that triggers a mandatory notified-body disclosure to the manufacturer.

The three levers: clock-stops, cost, and reporting

Three mechanisms do the actual work. First, the regulation sets maximum timelines for conformity assessment activities and caps how many times a notified body may stop that clock per phase to wait for a manufacturer's response to a non-compliance finding or a request for information — the regulation's text sets the exact cap per phase, and it is worth confirming against the Official Journal rather than a secondary summary before you build a submission plan around it. One exclusion matters operationally: when a notified body is waiting on an opinion from the European Medicines Agency, an expert panel, or an EU reference laboratory, that wait is suspended by operation of law and does not count against the limits at all.

  • Clock-stops, capped. A notified body can still pause the clock for a manufacturer's response, but only a bounded number of times per phase — confirm the exact figure in the Official Journal text for the phase you're in.
  • Cost transparency. If the actual cost of the conformity assessment rises more than 10% above the original estimate, the notified body must notify the manufacturer.
  • Rolling review, by agreement. Manufacturer and notified body may agree to a rolling review of technical documentation — submitted and assessed incrementally rather than as one block — but only where both sides agree to it.
  • Annual public reporting. Each notified body must publish, by 30 April every year starting in 2028, the percentage of assessments completed on time, the median time from application to certification, and the median total cost, and send the same report to its authority and the Commission.
Exceeding the maximum timeline is a disclosure event, not a guarantee. The predictability this regulation buys is accountability — not a deadline with teeth against the notified body. Why the cap isn't a shortcut

What this means for submission timing — and when it starts

The regulation generally applies from 25 February 2027. Agreements signed before that date continue under the prior framework rather than being pulled into the new timeline rules retroactively, and the recertification-specific provisions do not bind certificates expiring before 25 November 2027. For a manufacturer planning a 2027 submission, the practical question is not whether the new rules exist but which side of 25 February 2027 the notified body agreement governing that submission falls on. Build that question into your EU MDR & IVDR planning now, before the notified body agreement is drafted, because the agreement date — not the submission date — is what decides the framework.

A notified-body timeline readiness sequence
  1. Map your agreement dates against 25 February 2027. Know which framework will govern your next assessment before the agreement is signed.
  2. Negotiate rolling technical documentation review now. It requires mutual agreement — raise it at contracting, not after documentation assembly starts.
  3. Track clock-stops and cost notices into the project plan. These, not the headline maximum alone, are where the regulation gives real visibility.
  4. Treat 2028's public reporting as a future vendor-selection input. On-time percentage, median time, and median cost become comparable across notified bodies for the first time.

None of this changes which conformity assessment route a device needs, or whether its technical file gets sampled in full. What it changes is whether the review inside that route is predictable, disclosed, and — eventually — comparable across notified bodies. Manufacturers who treat 25 February 2027 as a CE marking strategy milestone, not a compliance footnote, are the ones who will actually benefit from the accountability the regulation creates rather than being surprised by its transition rules.

Frequently asked questions

Is Implementing Regulation (EU) 2026/977 already in effect?

It was adopted on 4 May 2026 and published in the Official Journal the next day, but its general obligations apply from 25 February 2027, and its annual public-reporting requirement applies from 1 January 2028. As of this writing it is adopted but not yet generally in force.

Does exceeding the maximum timeline force a notified body to issue a certificate?

No. Running past a maximum timeline is a disclosure and reporting event under the regulation, not grounds by itself for a notified body to be compelled to issue a certificate. The predictability this regulation buys is accountability, not an automatic deadline with teeth against the notified body.

Does the new regulation apply to conformity assessment agreements already signed?

Reporting on the regulation's transition provisions indicates agreements signed before 25 February 2027 continue under the prior framework, and the recertification provisions specifically do not apply to certificates expiring before 25 November 2027. Confirm your own agreement's status against the regulation's transition articles directly.

Sources & further reading

  1. European Commission. Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 on conformity assessment activities of notified bodies under Regulations (EU) 2017/745 and (EU) 2017/746. eur-lex.europa.eu
  2. European Commission. Medical Devices: New Implementing Regulation sets out uniform requirements for conformity assessment and notified bodies. ec.europa.eu

This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm current application dates, exact clock-stop limits, and transition provisions under Implementing Regulation (EU) 2026/977 with the European Commission, your notified body, or qualified counsel before acting.